Dental insurance is a type of contract that is represented by a policy and covers only the dental health or oral health of a person. Insurers have simplified their product offerings & made them straightforward with selective coverages and provide comparison of multiple dental treatments in terms of protection and premiums for selected coverages. Moreover, dental insurance reimburses several dental costs incurred by the patients and the insurers have been profiting from rise in number of individuals with high income, increased per capita earnings, and surge in working class population. For the purpose of analysis, the report of dental insurance market is segmented the basis of coverage, type, demographics, end user, and region. The highlights the various coverages available in the market, which include dental preferred provider organizations (DPPO), dental health maintenance organizations (DHMO), dental indemnity plans, and others. In addition, it covers various types of insurance offered, including major, basic, and preventive. Furthermore, it provides a detailed description on various demographics such as senior citizens, adults, and minors. The end users include individuals and corporates. An in-depth analysis across North America, Europe, Asia-Pacific, and LAMEA has been included in the study.

DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current study aims to assess the global DNA methylation market by focusing on evaluating products catering to the aforementioned definition. The current scenario of DNA methylation detection and diagnosis is mainly dominated by several diagnostic majors, such as Illumina, Inc., Thermo Fisher Scientific Inc., Merck Group, and QIAGEN N.V., which offer a wide variety of products ranging from molecular-genetic tests to sequencing instruments for the confirmatory detection and diagnosis of DNA methylation. These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.

Drug screening is used to identify prescription drugs and illicit drugs in urine, plasma, and other biological samples. Urine testing is the most commonly used sample type for drug screening. The report provides market dynamics and trends related to the global drug screening laboratory services market. In addition, it presents estimations and forecast of the drug screening services market majorly performed for various workplaces. The study estimates revenue generated from the services offered. The valuations comprise revenue generated from drug laboratory services. However, the report excludes revenues generated by counseling fees of doctors or healthcare providers who suggest various types of drug screening tests.

The report covers the detailed analysis of the trends, future estimations, and a thorough study of the global fish oil market on the basis of species and application. It analyzes government regulations, policies, and patents to provide information on the current market trends and suggests future growth opportunities globally. Furthermore, the study highlights Porter’s five forces analysis to determine the factors affecting the market growth. These factors include raw material prices, intense competition, end users, manufacturers, and suppliers. To understand the market, drivers, restraints, and opportunities are explained in the report. Furthermore, it includes the revenue generated from the sales of fish oil across North America, Europe, Asia- Pacific, and LAMEA.

The global infusion pumps and accessories market is primarily driven by rising incidence of the chronic diseases, such as cancer and others, coupled with the rising adoption of these devices, owing to broadening applications of infusion pumps. Currently, infusion pumps are widely used in the chemotherapy, diabetes management, and many other applications. The rising prevalence of these diseases, worldwide, is creating ample opportunities for market to grow. For instance, according to International Diabetes Federation (IDF), in 2019, there were approximately 463 people were living with diabetes and is estimated that the number is anticipated to grow to 700 million by 2045. In addition, technological advancements in the device technology, and companies' efforts in innovating products to meet the safety and increase the adoption of devices are likely to fuel the market growth. On the other hand, the market is being hindered by high cost of the infusion pumps, safety issues associated with the devices and infusion-related errors.

中国内地累计确诊85351例，累计病死率约5.4%。3月中旬后境外输入病例为主，7月中旬新疆出现小范围反弹。

港交所于2020 年09 月27 日披露京东健康招股说明书，公司拟与于港交所主板上市。京东健康成立于2018 年11 月30 日，为京东集团子公司，京东集团现持股81.04%。根据弗若斯特沙利文的报告，京东健康是2019 年中国最大的在线零售药房。截至2020 年6 月30 日，共逾1.5 亿名用户曾使用公司平台购买医药和健康产品或医疗健康服务。

本周行情：整体跑赢大盘，生物制药、药用辅料及包材涨幅较大本周医药指数上涨0.51%，万得全A 指数下跌3.72%，医药指数整体跑赢大盘4.23%。2020 年以来，医药指数整体跑赢大盘28.92%。子行业方面，本周11 个子行业中8 个出现上涨。生物制药（+5.77%）、药用辅料及包材（+3.66%）子行业涨幅较大，中药（-3.38%）、原料药（-2.35%）子行业跌幅较大。